Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib + lenalidomide + rituximab in relapsed/refractory mantle cell lymphoma
2013-005541-36Phase 2Completed
- Sponsor
- Nordic Lymphoma Group
- Start
- Sep 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib, lenalidomide and rituximab in mantle cell lymphoma (MCL), sponsored by Nordic Lymphoma Group. Primary endpoint: Overall response rate (ORR). Started Sep 2014; status: completed.
02
Drugs
ibrutiniblenalidomiderituximab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2013-005541-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005541-36.